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Tousled-like kinases stabilize replication forks  
and show synthetic lethality with checkpoint  
and PARP inhibitors
Sung-Bau Lee1,2*, Sandra Segura-Bayona3*, Marina Villamor-Payà3, Giulia Saredi1†, Matthew A. M. Todd1,4, 
Camille Stephan-Otto Attolini3, Ting-Yu Chang2, Travis H. Stracker3‡, Anja Groth1,4‡
DNA sequence and epigenetic information embedded in chromatin must be faithfully duplicated and transmitted 
to daughter cells during cell division. However, how chromatin assembly and DNA replication are integrated re-
mains unclear. We examined the contribution of the Tousled-like kinases 1 and 2 (TLK1/TLK2) to chromatin assem-
bly and maintenance of replication fork integrity. We show that TLK activity is required for DNA replication and 
replication-coupled nucleosome assembly and that lack of TLK activity leads to replication fork stalling and the 
accumulation of single-stranded DNA, a phenotype distinct from ASF1 depletion. Consistent with these results, 
sustained TLK depletion gives rise to replication-dependent DNA damage and p53-dependent cell cycle arrest in 
G1. We find that deficient replication-coupled de novo nucleosome assembly renders replication forks unstable 
and highly dependent on the ATR and CHK1 checkpoint kinases, as well as poly(adenosine 5′-diphosphate–ribose) 
polymerase (PARP) activity, to avoid collapse. Human cancer data revealed frequent up-regulation of TLK genes 
and an association with poor patient outcome in multiple types of cancer, and depletion of TLK activity leads to 
increased replication stress and DNA damage in a panel of cancer cells. Our results reveal a critical role for TLKs in 
chromatin replication and suppression of replication stress and identify a synergistic lethal relationship with check-
point signaling and PARP that could be exploited in treatment of a broad range of cancers.
INTRODUCTION
Faithful duplication of DNA and its organization into chromatin 
is essential to maintain genome integrity and function. During ge-
nome replication, progression of the replication machinery can be 
challenged by limitations in nucleotide supply and physical obsta-
cles on the DNA template, including naturally occurring DNA 
lesions and difficult to replicate secondary structures. To ensure 
correct and complete duplication of the genome, cells have evolved 
a network of safeguards and repair mechanisms that protect repli-
cation forks (1). When replication forks are challenged, long stretches 
of single-stranded DNA (ssDNA) can accumulate because of un-
coupling of the replicative helicase from stalled DNA polymerases 
(1). Replication protein A (RPA)–coated ssDNA, along with the 
9-1-1 (RAD9-RAD1-HUS1) DNA clamp complex and TOPBP1, 
recruits and activates ATR, the upstream kinase in the replication 
checkpoint. ATR activation and subsequent activation of CHK1 act 
to stabilize arrested forks, suppress late origin firing, and trigger ac-
tivation of DNA repair machinery to deal with lesions (1). In addi-
tion, poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) 
activity is required for CHK1 retention at stalled forks, activation of 
the S-phase checkpoint, and the restart of stalled replication forks 
(2, 3). Prolonged fork arrest poses a risk of fork collapse and gener-
ation of DNA double-strand breaks (DSBs) potentially due to nu-
clease attack (1).
DNA replication and checkpoint control is tightly integrated with 
histone dynamics and chromatin assembly (4), but little is known 
about how this is linked to fork protection mechanisms. The func-
tion of the H3-H4 chaperone ASF1 and the assembly of newly syn-
thesized DNA into chromatin are required for DNA replication in 
mammalian cells (5–7). The regulation of ASF1 has been linked to 
the Tousled-like kinases (TLKs), a relatively unexplored family of 
nuclear serine/threonine kinases whose activity peaks during un-
perturbed DNA replication and is regulated by CHK1. The TLKs 
could therefore act at the interface between DNA replication, chro-
matin assembly, and genome integrity (8–10).
Mammalian cells express two TLK isoforms, TLK1 and TLK2, which 
are highly active in S phase, can interact with each other, and are neg-
atively regulated by CHK1 (8–10). Recent studies have identified TLK1 
at replication sites (11) and observed an S-phase delay in TLK1- 
depleted cells (12). The histone H3-H4 chaperones ASF1a and 
ASF1b are the primary established TLK1 and TLK2 targets (13) and 
are required to deliver histones to CAF-1 and HIRA for replication- 
coupled and replication-independent chromatin assembly, respec-
tively (14). Recently, TLK1 was reported to phosphorylate RAD9—part 
of the 9-1-1 proliferating cell nuclear antigen (PCNA)–like clamp—
and this was linked to G2-M checkpoint release (12, 15), while other 
reports implicated TLK2, but not TLK1, in G2-M checkpoint recov-
ery through an ASF1a-mediated transcriptional regulation (16). How-
ever, TLK activity peaks in S phase, and its loss during early and 
rapid cell divisions in Drosophila and Caenorhabditis elegans causes 
severe chromatin and proliferation defects and cell death (17, 18), 
suggesting that TLKs serve central conserved functions during DNA 
replication.
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TLKs have been proposed to promote histone provision in S phase 
(11) based on the finding that phosphorylation of ASF1 stimulates 
histone H3-H4 binding and interaction with the downstream chap-
erones CAF-1 and HIRA. However, the requirement of TLK activity 
for DNA replication and chromatin assembly remains to be estab-
lished. Understanding the precise relationship of TLK activity to 
these processes is particularly important because TLK1/2, as S-phase 
active kinases, are attractive druggable targets for cancer therapy—a 
notion supported by recent evidence that amplification of TLK-ASF1 
signaling is indicative of poor prognosis in breast cancer (19, 20).
Here, we examine the relative impact of TLK1 and TLK2 deple-
tion and show that these enzymes are required for DNA replication 
and chromatin assembly. Depletion of TLK activity led to replication 
stress and impaired chromatin assembly, accumulation of DNA dam-
age, and subsequent cell cycle arrest. The deleterious effects of TLK 
depletion were exacerbated by treatment with replication checkpoint 
inhibitors and the PARP inhibitor olaparib. Inhibition of new histone 
biosynthesis, but not ASF1 depletion, recapitulated this synthetic 
lethality response, arguing that TLK activity protects replication 
fork stability by stimulating de novo histone deposition. Analysis of 
The Cancer Genome Atlas (TCGA) data sets revealed that amplifi-
cations of TLK-ASF1 pathway genes occur frequently in human 
cancers and the requirement for TLK activity to maintain genome 
integrity applies across multiple cancer types. Together, these data 
argue that TLK activity by promoting nucleosome assembly plays a 
central role in replication fork progression and that targeted inhibi-
tion of TLK1/2 could be an attractive strategy to enhance replica-
tion stress and augment the effects of ATR, CHK1, and PARP-1 
inhibitors in many types of cancers.
RESULTS
TLK2 is required for efficient DNA replication
TLK activity peaks during S phase, when DNA is replicated and 
packaged into chromatin (9). We therefore set out to investigate the 
influence of TLK activity on DNA replication by measuring the 
incorporation of thymidine analogs. The small interfering RNA 
(siRNA)–mediated depletion of TLK1 in U-2-OS cells did not af-
fect the number of 5-bromo-2′-deoxyuridine (BrdU)–positive cells 
(Fig. 1A), and we could readily generate stable TLK1 CRISPR 
(clustered regularly interspaced short palindromic repeats) knock-
outs from the MDA-MB-231 breast cancer cell line. These TLK1 
cells exhibited similar proliferation rates and levels of BrdU incor-
poration as the parental cells (Fig. 1B and fig. S1, A to D). Depletion 
of TLK2 reduced the rate of DNA replication and the overall num-
ber of BrdU-positive or 5-ethynyl-2′-deoxyuridine (EdU)–positive 
cells significantly (Fig. 1, A to E, and fig. S1E). Notably, the siRNA- 
mediated depletion of TLK2 also often resulted in the reduction of 
TLK1 protein levels, an effect that was more dramatic in U-2-OS 
cells than in MDA-MB-231 cultures (Fig. 1C), probably reflecting 
the fact that heterodimerization influences TLK1 stability (10). Stable 
expression of siRNA-resistant wild-type (WT) TLK2 rescued the 
replication defect of U-2-OS cells, whereas a kinase-dead (KD) mutant 
(D590A) (10) of TLK2 failed to do so (Fig. 1E and fig. S1F). These 
demonstrate that TLK2 promotes DNA replication through its 
kinase activity.
To further dissect the role of TLK2 in replication, we used DNA 
combing to analyze replicating DNA molecules to monitor fork 
elongation rates. We carried out the analysis 30 hours after siRNA 
treatment, the earliest time where a moderate reduction in EdU 
incorporation was evident (Fig. 1E and fig. S1, E and G). We incor-
porated 5-chloro-2′-deoxyuridine (CldU) into newly replicating 
DNA and then quantified elongation rates by measuring the length 
of CldU-labeled tracks. As a control, we included the CHK1 inhibi-
tor UCN-01, which triggers hyperactivation of cyclin-dependent 
kinase 2 (CDK2) kinase activity and slowdown of fork progression 
(21, 22), as indicated by reduced CldU track length (Fig. 1F) (21, 22). 
Similarly, siRNA-mediated depletion of TLK2 reduced fork speed 
substantially (Fig. 1F and fig. S1H). The loading of replication fork 
factors CDC45 and PCNA, but not prereplication complex com-
ponents ORC1 and MCM2, was increased upon TLK2 depletion 
(Fig. 1G), and CldU intertrack distances were reduced (fig. S1I). 
This mimicked the response to CHK1 inhibition and argued that, 
while origin licensing was not affected, origin firing was increased 
in cells depleted of TLK activity as expected when replication fork 
speed is reduced (fig. S1I) (1). Collectively, these results demon-
strated that multiple cell lines are dependent on TLK activity for 
DNA replication and indicated that impaired replication fork pro-
gression underlies the replication defect in cells lacking TLKs.
TLK activity is required for chromatin assembly
The histone chaperone ASF1 is a well-established TLK substrate (13), 
and its phosphorylation by TLK is proposed to facilitate provision 
of canonical histones H3.1-H4 and H3.2-H4 during DNA replica-
tion (11). Given that nucleosome assembly is required for replica-
tion fork progression (5), we asked whether TLK depletion influenced 
the deposition of new histones using U-2-OS cells stably expressing 
SNAP-tagged histones (Fig. 2A and fig. S2A) (23). We included 
both canonical histone H3.1 and the replacement variant H3.3, as 
ASF1 supplies histones to both replication-dependent and replication- 
independent pathways (14). Using quench-chase-pulse experi-
ments, we found that depletion of TLK activity using siRNA against 
TLK2 impaired de novo deposition of both histones H3.1 and H3.3 
(Fig. 2, B to D, and fig. S2B). However, because H3.1-H4 incorpora-
tion is replication-dependent, the observed defect in histone H3.1 
and H4 incorporation in TLK-depleted cells could potentially be sec-
ondary to impaired DNA replication or alterations in the cell cycle 
(Fig. 1, A to E, and fig. S2C). To resolve this point, we specifically 
assayed chromatin assembly on newly synthesized DNA, as previ-
ously described (5). We labeled replicating DNA with radioactive 
thymidine and measured the sensitivity of nascent chromatin to 
nuclease digestion (Fig. 2E). Consistent with previous work (5), 
inhibition of histone biosynthesis upon depletion of FLASH (24) 
strongly increased the accessibility of nascent chromatin to micro-
coccal nuclease (MNase) (Fig. 2F) and reduced DNA replication 
fork speed (fig. S2D). Following TLK depletion, nascent chromatin 
was also more sensitive to MNase digestion (Fig. 2F), demonstrat-
ing that TLK activity is required for efficient replication-coupled 
nucleosome assembly. Collectively, this shows that TLK activity 
promotes nucleosome assembly and maintains chromatin organi-
zation, extending previous findings that TLK phosphorylation of 
ASF1 stimulates histone binding and interaction with CAF-1 and 
HIRA (11).
Loss of TLK activity leads to DNA unwinding, checkpoint 
activation, and loss of viability
Replication fork stalling, origin hyperactivation, and defects in 
chromatin assembly have all been implicated in fork collapse and 
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genome instability (1, 5, 25). Sustained depletion of TLK2 in MDA-
MB-231 cells, on either a WT or TLK1 background, significantly 
increased the levels of chromatin-bound RPA, H2AX phosphoryl-
ation at S139 (H2AX), and phosphorylation of RPA at S4/S8 (Fig. 3, 
A to C, and fig. S3, A and B). Similar results were obtained in U-2-
OS cells, where TLK depletion led to accumulation of chromatin- 
bound RPA and increased phosphorylation of RPA at S4/S8, a marker 
of replication fork collapse (Fig. 3, D to F). This was indicative of 
increased ssDNA accumulation, checkpoint activation, and replica-
tion fork collapse (1), and as expected for a genuine replication 
stress response, depletion of the replication initiation factor CDC45 
blocked RPA accumulation and DNA damage (Fig. 3, E and F). 
Consistent with these results in human cells, conditional depletion 
of both TLK1 and TLK2 in mouse embryonic fibroblasts resulted in 
reduced DNA replication and elevated replication stress signaling 
(fig. S3, C and D).
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Fig. 1. TLK2 is required for efficient DNA replication. (A) U-2-OS cells were pulsed with BrdU 48 hours after transfection with siRNAs against TLK1 or TLK2. The percent-
age of S-phase cells was subsequently quantified by analysis of DNA content using propidium iodide (PI) and staining for BrdU. Means and SD from technical replicates 
performed in at least biological duplicate are shown. (B) The percentage of S-phase cells was quantified in MDA-MB-231 cells pulsed with BrdU 72 hours after transfection 
and analyzed as in (A). (C) Western blot analysis of TLK1 and TLK2 from whole-cell lysates of U-2-OS (top) or MDA-MB-231 cells (bottom) 48 or 72 hours after siRNA trans-
fection, respectively. (D) Immunofluorescence analysis of EdU incorporation in U-2-OS cells pulsed with EdU 30 hours after TLK2 siRNA transfection. Representative images 
are shown with PCNA as a marker for S-phase cells. (E) DNA replication in complemented U-2-OS cells. U-2-OS cells stably expressing siRNA-resistant WT or KD TLK2 were 
analyzed as in (D). See fig. S1F for Western blots for TLK2-WT or KD. EdU average intensities relative to parental cells from n = 3 independent biological replicates are 
shown with means and SD. One-sample and unpaired two-tailed t tests were used for statistical analysis of parental U-2-OS cells and complemented cell lines (TLK2WT 
and KD), respectively. **P < 0.01; n.s., not significant; a.u., arbitrary units. (F) Analysis of replication fork speed by DNA combing analysis. Length of CldU-labeled tracks 
(n > 250) was measured. One representative experiment of two biological replicates is shown, and median is indicated by a red line. (G) Analysis of replication factor 
chromatin loading in U-2-OS cells treated with or without UCN-01 30 hours after transfection. Cells were preextracted, and the chromatin pellet was subjected to Western 
blotting. One representative experiment of two biological replicates is shown.
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TLK-depleted cells showed reduced colony-forming capacity, 
providing evidence of reduced viability and/or proliferative ca-
pacity (Fig. 3G). DNA damage signaling elicits a delay in cell cycle 
progression due to the activation of cell cycle checkpoints. Upon 
sustained TLK2 depletion, we observed a moderate increase in 
p53, a major inducer of G1-S checkpoint arrest, along with a p53- 
dependent induction of the CDK inhibitor p21 (Fig. 3H and fig. S3E). 
Consistent with this finding, the number of S-phase cells was pro-
gressively reduced from 48 to 72 hours of TLK2 depletion (fig. S1, E 
and G), and nocodazole trap experiments indicated that G1-S transi-
tion was impaired (Fig. 3I and fig. S3, F and G). Co-depletion of p53 
was sufficient to partially rescue this block in G1-S transition (fig. S3G), 
arguing that, as DNA damage accumulates during prolonged TLK2 
depletion, the p53-p21 checkpoint is activated and blocks S-phase 
entry.
TLK depletion is synthetic lethal with checkpoint 
inactivation and PARP inhibition
Whereas sustained TLK depletion for 48 to 72 hours generated DNA 
damage (Fig. 3), short-term reduction of TLK activity impaired fork 
progression without eliciting a strong DNA damage response 
(Figs. 1F and 4, A and B, and fig. S4, A and B). However, we noted 
that the combined inhibition of TLK2 and the replication check-
point kinase CHK1 strongly augmented RPA loading at early time 
points (Fig. 1G). We reasoned that this effect might reflect the fact 
that destabilized replication forks in TLK-depleted cells strongly 
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Fig. 2. TLK2 is required for replication-coupled chromatin assembly. (A) Experimental design for assaying histone incorporation in cell lines stably expressing SNAP-
tag histones H3.1 and H3.3. For quench (Q)–chase–pulse (P) experiments, U-2-OS cells were pulsed with SNAP-Block, chased for 7 hours, and then pulsed with TMR-Star. 
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observed for siTLK1, P = 0.0005 for siTLK2, and P = 0.0120 for siTLK1+2. (E and F) Analysis of replication stress response in U-2-OS cells transfected with TLK2 siRNAs alone 
or together with CDC45 siRNAs for 30 hours (E) or 48 hours (F). One representative experiment of two biological replicates is shown for (E) and (F). (G) Colony formation 
assay in U-2-OS cells transfected with TLK siRNAs. Data represent means and SEM of biological replicates (n = 5 for siCont, n = 4 for siTLK2#1, and n = 2 for siTLK2#2), 
each done at least in technical duplicates. A one-sample t test was used for statistical analysis. ***P = 0.0001 for siTLK2#1 and *P = 0.0324 for siTLK2#2. (H) Western 
blot analysis of U-2-OS cell lysates after 48 hours of siRNA transfection, representative of three independent experiments. (I) Cell cycle progression analyzed by flow 
cytometry of cells treated with nocodazole and stained with PI. The experimental design (left) and representative cell cycle profiles (right) from one of n = 3 biological 
replicates are shown.
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rely on the replication checkpoint to avoid collapse, and we there-
fore addressed the possibility of a synthetic sickness between these 
two pathways. As expected from previous work (22), we observed 
DNA damage signaling in cells treated with the checkpoint inhibitor 
UCN-01 (Fig. 4A and fig. S4A). Co-depletion of TLK2 substantially 
enhanced this response (Fig. 4A and fig. S4A), elevating the phos-
phorylation of ATM-S1981, CHK2-T68, p53-S15, RPA2-S4/S8, 
and H2AX. Notably, these experiments were performed at 24 hours 
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Fig. 4. TLK depletion causes genomic instability and sensitizes cells to checkpoint inactivation and PARP inhibition. (A) Analysis of DNA damage signaling in U-2-
OS cells 24 hours after siRNA transfection and treatment with or without UCN-01 for 2 hours. One representative experiment of three biological replicates is shown. 
(B) HTM analysis of RPA accumulation and H2AX in TLK2-depleted U-2-OS cells treated with UCN-01 alone or together with roscovitine for 2 hours. One representative 
experiment of two biological replicates is shown (n > 1800). (C) PFGE analysis of DNA DSBs in U-2-OS cells transfected with siRNAs for 24 hours and treated with UCN-01 
for 4 hours. Representative result (left) and quantification (right) of DNA breaks relative to untreated control from n = 3 independent experiments are shown with the 
means and SD. An unpaired two-tailed t test was used for statistical analysis. **P < 0.01. IR, ionizing radiation, 20 Gy. (D) Sensitivity of TLK-depleted cells to the CHK1 in-
hibitor AZD7762 measured by colony formation assay. Representative experiment of two biological replicates performed in technical duplicate is shown. (E) Sensitivity 
to PARP inhibitor olaparib measured by colony formation assay; representative images are shown. Means and range of two biological replicates performed in technical 
duplicate are shown. (F) Western blotting of RPA and phospho-RPA following TLK depletion and olaparib treatment in U-2-OS cells.
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after transfection before any detectable DNA damage occurred in 
cells depleted for TLK2. Similar results were obtained in U-2-OS 
cells treated with two different CHK1 inhibitors (Gö-6976 and 
MK-8776; fig. S4B), in MDA-MB-231 cells treated with a CHK1 in-
hibitor (AZD7762; fig. S4C), and upon treatment with ATR inhib-
itors (AZ20 and ETP-46464; fig. S4, D and E) (26–29).
High-content imaging showed that DNA damage occurred in 
cells with hyperloading of RPA on chromatin (Fig. 4B), as previ-
ously found upon replication fork collapse in response to ATR inhi-
bition in hydroxyurea-treated cells (30). Cotreatment with the CDK2 
inhibitor roscovitine suppressed both RPA accumulation and DNA 
damage (Fig. 4B), suggesting that fork collapse was a result of CDK2- 
induced unscheduled origin firing and, possibly, titration of repli-
cation factors away from forks with chromatin assembly defects 
(30, 31). The application of pulsed-field gel electrophoresis (PFGE) 
to directly measure DSBs revealed that combined inactivation of 
TLK2 and inhibition of the replication checkpoint synergistically 
increased the numbers of DSBs observed (Fig. 4C). Consistent with 
this result, TLK2-depleted MDA-MB-231 cells displayed a further 
reduction in colony formation capacity following CHK1 inhibition 
by AZD7762 (Fig. 4D), and TLK2 depletion also enhanced the cyto-
toxicity of CHK1 inhibitors in U-2-OS cells (fig. S4F).
In addition to CHK1 and ATR inhibitors, the PARP inhibitor 
olaparib is of interest in current clinical studies, as it was shown to cause 
synthetic phenotypes with defects in homologous recombination– 
mediated repair (32, 33). We therefore asked whether olaparib would 
enhance the defects of TLK-depleted cells in a manner similar to 
checkpoint inhibition. We found that the addition of olaparib 
strongly decreased the survival of MDA-MB-231 cells depleted for 
TLK activity (Fig. 4E and fig. S4G) and that this was accompanied 
by enhanced RPA phosphorylation (Fig. 4F and fig. S4H).
De novo nucleosome assembly defects synergize with 
checkpoint inhibition
New histone deposition and nucleosome assembly are required for 
replication fork progression (5), and nucleosome assembly defects 
lead to a gradual decline in replication fork stability (5), as observed 
in cells depleted for TLK activity. However, DNA unwinding at 
stalled replication forks is strongly impaired in ASF1-depleted cells 
(6, 7), in contrast to what we observed upon TLK depletion (Fig. 3, 
A to D). It was thus important to address whether the synthetic le-
thal relationships were linked to the function of TLKs in chromatin 
assembly or to a distinct function that has yet to be identified. We 
thus compared TLK depletion to depletion of either ASF1 (a and b) 
or FLASH, a key regulator of histone biosynthesis (24), in a time 
course analysis. At 48 hours after transfection, when extensive RPA 
phosphorylation was evident in TLK-depleted cells, little signaling 
was observed in cells depleted for ASF1 (a and b) (Fig. 5A). In con-
trast, FLASH depletion led to increased RPA phosphorylation, albeit 
to lower levels than TLK depletion, indicating that replication stress 
was induced (Fig. 5A).
Next, we addressed whether defects in ASF1 function or in new 
histone biosynthesis per se were sufficient to sensitize cells to treat-
ment with checkpoint inhibitors. Similar to TLK2 depletion, FLASH 
knockdown also exacerbated UCN-01–induced DNA damage, mainly 
in cells exhibiting an accumulation of RPA-coated ssDNA (Fig. 5, 
B and C). Surprisingly, this synthetic relationship was not recapitu-
lated by depletion of ASF1 (a and b) (Fig. 5C), suggesting that fork 
arrest differs in TLK- and ASF1-depleted cells. As ASF1 is the most 
well-characterized substrate of TLKs, we analyzed the effects of co- 
depleting TLK1/2 and ASF1a/b. This led to the suppression of RPA 
phosphorylation observed following TLK depletion (Fig. 5D), fur-
ther confirming that ASF1 is necessary for unwinding and indicat-
ing that its phosphorylation by TLKs is dispensable for this function. 
This was corroborated by the overexpression of a nonphosphoryl-
atable ASF1a mutant (ASF1a-4A) that enhanced the levels of RPA 
phosphorylation observed following TLK depletion (Fig. 5E). In ad-
dition to delivering new histones to CAF-1 for de novo deposition, 
ASF1 has been implicated in histone recycling together with MCM2-7 
(6, 34, 35). Given that inhibition of new histone biosynthesis mim-
ics the hypersensitivity to checkpoint inhibitors in TLK-depleted 
cells, the most parsimonious explanation is that this phenotype is 
linked specifically to de novo histone deposition and not to other 
functions of ASF1 in histone dynamics. We cannot exclude that 
TLKs serve functions at the replication fork independent of his-
tones, for example, through targets other than ASF1 (36). However, 
we note that the exacerbated DNA damage response in FLASH- 
depleted cells could be suppressed by roscovitine treatment (Fig. 5C), 
suggesting that it was linked to origin hyperactivation, as in the case 
of TLK depletion. Together, these results indicated that replication 
forks stalled because of de novo nucleosome assembly defects are 
vulnerable to collapse and that cells rely on basal levels of check-
point signaling to prevent fork collapse, rampant genomic instabil-
ity, and cell death.
TLK levels influence cancer cell proliferation
Previous work has linked high expression levels of either TLK2 or 
ASF1B with poor patient outcome in subsets of breast cancer pa-
tients (19, 20). As our results indicated that TLK activity was critical 
for nucleosome assembly during DNA synthesis and for replication 
fork stability, we considered that it was likely to be maintained or 
amplified in many cancer cell types to support proliferation. We 
examined the available data sets from TCGA for copy number alter-
ations (CNAs), mutations, or relative expression of the TLK1 and 
TLK2 genes (table S1). As a basis of comparison, we also included 
ASF1A/B, ATR, and CHEK1 (encoding CHK1), as well as several 
genes related to proliferation (MKI67, MCM2, and E2F1) and well- 
characterized tumor suppressors or oncogenes (TP53, ATM, MYC, 
PTEN, and EGFR) to provide scale for comparison (table S2). Ana-
lyzing data from more than 7000 patient samples (n = 7343), we 
found that TLK1, TLK2, and ASF1B more frequently exhibited copy 
number increases (CNIs) rather than copy number decreases (CNDs) 
or mutations (Fig. 6, A and B, and fig. S5, A to C). In contrast, CNDs 
were the most frequent type of alteration observed for ASF1A, con-
sistent with recent reports (Fig. 6A and fig. S5B) (37). As alterations 
in gene expression can also occur independently of CNAs, we ex-
amined gene expression in the data sets where it was available and 
asked whether there were correlations between the expression of 
TLK-ASF1 and ATR-CHEK1 genes, as well as the proliferation mark-
ers MKI67 and MCM2 (fig. S5D). At the expression level, TLK1 and 
ASF1A showed a strong correlation with each other, and neither 
gene was significantly correlated with the expression of prolifera-
tion markers (MKI67 or MCM2). In contrast, expression of ASF1B 
and CHEK1 showed a highly significant correlation with the expres-
sion of both MKI67 and MCM2 across nearly all TCGA data sets, 
supporting the proposed utility of ASF1B as a proliferation marker 
(fig. S5D and table S3) (19). TLK2 expression also correlated posi-
tively with proliferative markers across the pan-cancer data set, albeit 
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Fig. 5. Defects in new histone deposition are synthetic lethal with checkpoint inhibition. (A) Time course Western blot analysis of replication stress signaling follow-
ing the siRNA depletion of TLK1/2, ASF1a/b, and FLASH in U-2-OS cells. (B) Analysis of DNA damage signaling in U-2-OS cells treated with siRNAs and UCN-01 for 24 and 
2 hours, respectively. One representative experiment of two biological replicates is shown. (C) HTM analysis of RPA accumulation and H2AX in ASF1a/b or FLASH-depleted 
U-2-OS cells as in Fig.  4B (left). Western blot controls for siRNA treatment (right). One representative experiment of two biological replicates is shown (n > 4800). (D) West-
ern blot analysis of replication stress signaling following the siRNA depletion of the indicated combinations of TLK1/2 and ASF1a/b in U-2-OS cells. One representative 
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siTLK2 (+Tet), and P = 0.0484 was observed.
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Fig. 6. TLKs are amplified and suppress replication stress in multiple cancer types. (A) Box plots of the fraction of patients with CNIs or CNDs among the TCGA 
cohorts (details in table S1) for the indicated genes. Box plots show first to third quartiles, with whiskers at third quartile +1.5*IQR (interquartile range) and first quartile 
−1.5*IQR. Analysis of mutation frequency for the same genes is provided in fig. S5A. (B) Heat map showing the percentage of samples in individual TCGA cohorts with 
CNIs for the indicated gene. TCGA cohort abbreviations and chromosome locations of each gene are provided in tables S1 and S2, and heat maps for CNDs and mutations 
are provided in fig. S5 (B and C). (C to E) Kaplan-Meier plots of multivariate disease-free survival analysis of the TCGA uveal melanoma (uvm; D), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (cesc; E), and cervical kidney renal papillary cell carcinoma (kirp; F) cohorts based on the expression of the indicated gene. 
The hazard ratios (HR) and [likelihood ratio test (LRT)] P values were calculated using expression as a continuous variable: uvm (low, n = 30; high, n = 29), HR = 3.29 (1.44 
to 7.53) for TLK1(LRT-pv = 0.0007744) and HR = 2.52 (1.19 to 5.35) for TLK2(LRT-pv = 0.0064077); cesc (low and high, n = 84), HR = 1.49 (1.04 to 2.12) for TLK1(LRT-pv = 
0.031458) and HR = 1.45 (1.06 to 1.97) for TLK2(LRT-pv = 0.028423); kirp (low, n = 112; high, n = 110), HR = 0.80 (0.58 to 1.11) for TLK1(LRT-pv = 0.17713) and HR = 1.28 (0.99 
to 1.66) for TLK2(LRT-pv = 0.075713). Additional supporting data are provided in tables S4 and S5. (F) HTM analysis of H2AX 48 hours after siRNA treatment in the indi-
cated cell line. One representative experiment of two biological replicates is shown. Median is indicated by a red line. (G) Representative image examples for the quanti-
fication in (F). Staining for H2AX and TLK1 (to assess depletion levels) is shown. A minimum of 150 nuclei were evaluated for each cell line in each experiment. (H) Model 
for the combined influence of chromatin assembly and checkpoint signaling in the protection of stalled replication forks. Assembly of new nucleosomes on replicating 
DNA is required for fork progression and is dependent on ASF1-mediated histone provision. Reduced TLK activity impairs de novo nucleosome assembly, slowing down 
replication forks and reducing their stability. Under these circumstances, basal checkpoint and PARP activity are required to maintain the stability of stalled forks and 
prevent new origin firing that would accelerate fork collapse and increase levels of DNA damage.
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to a much lesser degree than ASF1B, and was significantly correlated 
with MKI67 expression in a more limited subset of individual can-
cers (fig. S5D and table S3). Together, these data demonstrated that 
TLK1, TLK2, and ASF1B CNIs occur more frequently than other 
types of alterations and in diverse cancer types.
We next wanted to examine the potential relationship between 
the genomic alterations or expression differences of TLK1 and TLK2 
genes and patient outcome. We first carried out a univariate analy-
sis to identify cancer types where TLK1 or TLK2 expression was 
significantly associated with survival or other clinical parameters 
(table S4). We then performed a multivariate analysis on several of 
these cohorts that showed high levels of CNIs (Fig. 6B) or high ex-
pression of TLK1 and TLK2 (fig. S5E). We included age, sex, MKI67 
expression level (proliferation), and tumor stage as covariables to 
determine whether expression levels of TLK1 or TLK2 significantly 
correlated with patient outcomes. High expression levels of both 
TLK1 and TLK2 correlated with reduced disease-free survival in the 
uveal melanoma (uvm_tcga) and cervical squamous cell carcinoma 
and endocervical adenocarcinoma (cesc_tcga) cohorts (Fig. 6, C and 
D). Furthermore, high expression of TLK2, but not of TLK1, was 
associated with reduced disease-free survival in kidney renal papil-
lary cell carcinoma (kirp_tcga), which was among the cohorts that 
exhibited the highest number of TLK2 CNIs among the TCGA data 
sets (Fig. 6E), as well as estrogen receptor–positive breast cancer, as 
previously reported (fig. S5F) (20). Collectively, these results show 
that the TLK-ASF pathway is amplified frequently in many cancer 
types and that, in several cases, high expression of TLK1 and TLK2 
correlates with poor patient outcome, further suggesting that TLK 
kinase activity may be a valuable therapeutic target that can en-
hance the efficacy of checkpoint or PARP inhibitors in a variety of 
cancer types.
The analysis of human cancer data suggested that TLK activity 
may be higher in many cancers, potentially reflecting a dependency 
on TLK activity to suppress replication stress. We therefore exam-
ined the effects of total TLK depletion in a panel of human cancer 
cell lines from different tissues, including breast, lung, liver, colon, 
and kidney. Depletion of both TLK1 and TLK2 in most of the cell 
lines examined led to increased phosphorylation of H2AX and RPA, 
although the extent of the response was variable (Fig. 6F and fig. 
S5G). We also observed that, while all cell lines seemed to re s pond 
to TLK depletion with replication stress signaling, those with higher 
levels of basal replication stress tended to be more sensitive. For 
example, NCI-H226 lung cancer cells or SW480 colon cancer cells 
showed higher basal levels of H2AX and a much stronger increase 
following TLK depletion (Fig. 6, F and G). This prominent DNA 
damage induction upon TLK depletion may indicate that those tu-
mors that rapidly proliferate and exhibit higher levels of oncogene- 
induced replication stress could also be more susceptible to TLK 
inhibition, alone or in combination with checkpoint or PARP 
inhibitors (Fig. 6H).
DISCUSSION
Here, we demonstrate a key role for TLK activity in promoting 
chromatin assembly and maintaining replication fork stability. The 
depletion of TLK activity impaired nucleosome assembly and led to 
replication-coupled ssDNA accumulation and fork stalling. Over 
time, DNA damage accumulated and induced a p53-dependent G1 
arrest. In cells experiencing short-term TLK depletion or histone 
deprivation, inactivation of the replication checkpoint led to mas-
sive accumulation of DSBs and loss of viability. This line of evi-
dence argues that TLK activity governs replication fork integrity 
and chromatin restoration on newly synthesized DNA, with check-
point kinases and PARP activity being crucial to prevent the collapse 
of forks arrested with chromatin assembly defects in the absence of 
TLK activity (Fig. 6H).
Our work shows that proper control of TLK activity is critical for 
chromosomal integrity and survival in cancer cells. Furthermore, 
it also provides an explanation as to why the loss of TLK activity 
during early and rapid cell divisions in Drosophila and C. elegans 
causes severe chromatin and proliferation defects and cell death 
(17, 18). Chromatin is central to all DNA-based processes and gov-
erns cell fate specification as well as genome integrity. Failure to 
assemble the newly synthesized DNA into chromatin, as a result of 
histone deprivation (5) or loss of CAF1 (38), ASF1 (6), or TLK1/2 
(this work), causes severe DNA replication defects. Available evi-
dence indicates that ASF1 is the prime TLK target in metazoans 
(13, 17, 18) and that it coordinates DNA synthesis with histone sup-
ply for chromatin assembly (11). However, TLK depletion does not 
simply recapitulate the phenotype of ASF1 loss of function. Loss of 
ASF1, as well as inhibition of histone biosynthesis, reduces replica-
tion fork speed and arrests cells in S phase (5, 6). In this setting, ex-
posure of ssDNA is not evident at stalled forks (5, 6). In contrast, 
lack of TLK activity reduces fork speed concomitant with accumu-
lation of ssDNA. While this might reflect that the TLKs have other 
targets, such as RAD9 (12, 15), our data support that ASF1 is phys-
ically required for unwinding through a function that is independent 
of its phosphorylation by TLKs (Fig. 5, D and F). Given that, in ad-
dition to delivery of new histones, ASF1 forms a histone-dependent 
complex with the MCM2-7 helicase that may control DNA unwind-
ing and ssDNA exposure (6, 35), we favor that TLK-independent 
functions of ASF1 in helicase regulation explain the different pheno-
types of TLK- and ASF1-depleted cells. We find that, in contrast to 
ASF1 depletion, inhibition of new histone biosynthesis leads to low 
levels of replication stress and, most remarkably, mimics the hyper-
sensitivity of TLK-depleted cells to checkpoint inhibitors. This points 
toward defective new histone deposition as a major contributor to 
fork instability in TLK2-depleted cells.
It has been demonstrated that TLK activity is inhibited by CHK1 
phosphorylation upon DNA damage (8, 9), indicating that the re-
s ponses are interlinked. Nevertheless, it is remarkable that concom-
itant depletion of TLK and inhibition of CHK1 or ATR activity 
showed strong synergistic effects, leading to genome breakage and 
lethality. Given that new histones via H4K20me0 provide an im-
portant platform for recruitment of the TONSL-MMS22L homolo-
gous recombination complex (39, 40), we propose that impaired 
nucleosome assembly impairs TONSL-MMS22L recruitment in the 
absence of TLK activity and sensitizes replication forks for collapse 
upon CHK1-dependent new origin firing and RPA exhaustion (30). 
This model is consistent with our finding that roscovitine prevents 
fork collapse in this setting and with the recent finding that long-
term depletion of CAF-1 and ASF1 for 72 hours impairs recruitment 
of TONSL-MMS22L to DNA DSBs (25).
Both TLK1 and TLK2 target ASF1 (13), but specialized functions 
for TLK1 and TLK2 have been proposed (12, 15, 16, 20). We could 
generate TLK1-deleted MDA-MB-231 cell lines, but we were un-
able to propagate lines that initially appeared to have lost TLK2 
(fig. S1A). Thus, we cannot exclude a TLK2-specific function 
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important for cell viability. However, our data are most compatible 
with redundant functions of TLK1/2 in chromatin assembly and 
suppression of replication fork stability, with their relative levels 
and, potentially, regulation varying across different cell types. This 
inference is consistent with previous conclusions from the study of 
knockout mice (36). Our analysis of genomic data from more than 
7000 patients in the TCGA data sets revealed that amplifications were 
the most common genomic alteration observed for either TLK1 or 
TLK2, as well as ASF1B, while few mutations or deletions were found 
in either of these genes. We have extended previous observations from 
the analysis of breast cancer (20, 41) and showed that high expres-
sion of both TLK1 and TLK2 is associated with reduced disease-free 
survival in additional cancer types from multiple tissues. Given the 
central role of TLKs in promoting histone provision during DNA 
replication, we propose that TLK activity is likely to be important 
for genomic stability in most proliferating cells and is thus a poten-
tially valid target in many types of highly proliferative cancers, re-
gardless of the association between expression and patient outcome. 
This proposition is further supported by the observation that TLK 
depletion leads to increased replication stress across a wide variety 
of cancer types (Fig. 6F and fig. S5G).
Together, we have shown that loss of TLK activity cripples chro-
matin assembly and fork stability, suggesting that highly prolifera-
tive cancer cells may generally require the integrity, and in some 
cases the amplification, of TLK-ASF1 signaling to support elevated 
levels of DNA replication and reduce toxic replication stress. The 
development of specific TLK1 and TLK2 inhibitors may therefore 
provide new therapeutic opportunities in a broad range of cancers 
(42), particularly in conjunction with ATR, CHK1, and PARP in-
hi bitors, as cells with reduced TLK activity become highly dependent 
on the ATR-CHK1–mediated replication checkpoint and PARP 
activity for survival.
MATERIALS AND METHODS
Study design
All experiments were carried out using a minimum of two biologi-
cal replicates. No statistical method was used to predetermine sample 
size. No samples were excluded from the analyses. The experiments 
were not randomized, and investigators were not blinded to alloca-
tion during experiments and outcome assessment. The primary re-
search objectives were to test the hypothesis that TLK activity was 
required for DNA replication. The resulting data led to the second-
ary hypotheses that TLK depletion would synergize with agents that 
exacerbate replication stress (namely, checkpoint and PARP inhibi-
tors) and that TLK activity would be beneficial to many types of can-
cer cells. Experimental design was primarily controlled laboratory 
experiments using standard cell culture techniques. It also involved 
the retrospective statistical analysis of TCGA cancer data sets.
Cell culture, stable cell lines, viral production,  
and drug treatment
U-2-OS, TIG3, MDA-MB-231, T47D, A549, SW48, HT29, SW480, 
and PLC/PRF/5 cells were grown in Dulbecco’s modified Eagle’s 
medium (Invitrogen); BT-20, HepG2, and ACHN cells were grown in 
minimum essential medium (Invitrogen); and NCI-H1395, NCI-H226, 
SNU449, and 786-O cells were grown in RPMI 1640 (Invitrogen), 
all with 10% fetal bovine serum (HyClone or Sigma) and 1% 
penicillin/streptomycin. Lentivirus was produced (Applied Biolog-
ical Materials Inc.) using pLenti6/UbC/V5-Dest (Invitrogen) with 
TLK2 WT or KD mutant (D591A) (10) resistant to siTLK2#1. U-2-
OS cells were infected with the virus supernatant supplemented 
with polybrene (Millipore) and subjected to single-clone selection 
with blasticidin (5 g/ml). SNAP-tag histone lines were generated 
using the retrovirus vector pBABE-Blast-H3.1, H3.3, or H4-SNAP-
3XHA [gift from L. Jansen (43)]. U-2-OS cells were infected with 
the virus supernatant supplemented with polybrene (Millipore) and 
selected with blasticidin (2.5 g/ml). U-2-OS Flp-In inducible cell 
lines expressing ASF1a 4A were previously described (11). For 
expression of HA/Flag-ASF1a 4A mutant, cells were induced with 
tetracycline (1 g/ml) for 24 hours. For siRNA transfection, cells 
were transfected with siRNAs at a final concentration of 50 to 
100 nM (Sigma) using Oligofectamine or Lipofectamine RNAiMAX 
(Invitrogen). Oligo sequences, generation of knockout cell lines 
using CRISPR/CAS9, drug treatments, and other details can be found 
in Supplementary Materials and Methods.
Immunocytochemistry and microscopy
Cells were preextracted with CSK-T [10 mM Pipes (pH 7), 100 mM 
NaCl, 300 mM sucrose, 3 mM MgCl2, 0.5% Triton X-100], fixed 
with 2% formaldehyde, and processed as described (7). EdU staining 
was performed using the Click-iT EdU Alexa Fluor 488/647 High- 
Throughput Imaging (HCS) Assay Kit (Invitrogen) according to the 
manufacturer’s instructions. In brief, cells were labeled with 40 M 
EdU for 15 min, preextracted, fixed, and imaged. The treatment of 
cold methanol at −20°C for 15 min was used for antigen retrieval of 
endogenous PCNA. Images were collected using a DeltaVision system 
(Applied Precision) with UApo/340 40×/1.35 numerical aperture 
(NA) oil objective lens or ScanR system with UPlanSApo 20×/0.75 NA 
objective lens. All images in the individual panels were acquired under 
room temperature with the same settings and adjusted for brightness 
and contrast identically using Adobe Photoshop CS6. Analysis was 
done with SoftWoRx software (Applied Precision), Volocity image 
analysis software (PerkinElmer), or ScanR analysis software. All exper-
iments were carried out in biological triplicates, and mean intensities 
are displayed in graphs unless otherwise indicated.
For HTM, cells grown in Lab-Tek II Chamber slides (Labclinics) 
were preextracted in 0.2% Triton X-100/phosphate-buffered saline 
(PBS) and fixed in 4% paraformaldehyde (PFA). Fixed cells were 
blocked in 3% bovine serum albumin (BSA)/0.1% Tween/PBS for 
1 hour and stained. Forty-eight images per well were automatically 
acquired with a robotized fluorescence microscopy station (ScanR, 
Olympus) at ×40 magnification and nonsaturating conditions. Im-
ages were segmented using the DAPI staining to generate masks 
matching cell nuclei from which the corresponding signals were cal-
culated using an in-house–developed package based on CellProfiler. 
Antibody information and technical details can be found in Supple-
mentary Materials and Methods.
Cell cycle and BrdU labeling analysis by flow cytometry
Fluorescence-activated cell sorting (FACS) analysis of cell cycle was 
described previously (5). In brief, cells were fixed overnight in ice-
cold ethanol (70%), stained with PI [50 g/ml in PBS supplemented 
with ribonuclease (RNase) A (0.25 mg/ml)] for 45 min at 37°C, and 
analyzed by a BD FACSCalibur equipped with CellQuest software. 
Data were analyzed and processed by FlowJo (version 8.8.4). For 
BrdU labeling, cells were pulsed with 10 M BrdU for 1 hour (U-2-OS) 
or 4 hours (MDA-MB-231) and fixed overnight with 70% ethanol. 
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DNA was denatured with 0.1 M HCl and incubated at 100°C, and 
BrdU was detected using the BD Pharmingen FITC Mouse Anti- 
BrdU Set Antibody (BD Biosciences). Cells were resuspended in 
400 l of PBS containing PI (25 g/ml) and RNase A (0.1 mg/ml) 
and subjected to FACS analysis. The percentage of BrdU-positive 
cells was analyzed with FlowJo software. Results are representative 
of biological duplicates, at a minimum.
Clonogenic assay
siRNA-transfected U-2-OS or MDA-MB-231 cells were seeded onto 
six-well plates in technical triplicates or on 6-cm plates in technical 
duplicates. After 8 to 14 days, cells were fixed and colonies were 
stained with crystal violet (Sigma-Aldrich). For colony formation 
capacity, graphs show the average of at least two biological repli-
cates and SEM. For survival analysis upon drug treatments, MDA-
MB-231 cells were seeded according to the plating efficiency. After 
24 hours of plating, cells were treated with AZD7762 for 24 hours 
and then washed and grown in fresh medium or were treated with 
olaparib and left in the culture continuously. Cells were incubated 
at 37°C for 10 to 14 days. Colonies were fixed and stained as de-
s cribed above. The colonies were counted using an in-house–built 
ImageJ macro using a Trainable Weka Segmentation plugin. On the 
basis of the colony number, plating efficiency (PE = number of col-
onies formed/number of cells seeded) and surviving fraction (SF = 
number of colonies formed after siRNA treatment/number of cells 
seeded × PE) were calculated and plotted.
MNase digestion assay
Chromatin was prelabeled with [14C]thymidine (0.5 pCi/ml) for 
24 hours before siRNA transfection. Thirty hours after transfection, 
nascent chromatin was labeled with [3H]thymidine (25 nCi/ml). To 
compensate for lower replication rate in TLK2- and FLASH-depleted 
cells, labeling times were adjusted to obtain similar [3H]thymidine 
incorporation (10, 15, and 30 min for siRNA control, siTLK2, and 
siFLASH, respectively). Cells were lysed in hypotonic buffer [10 mM 
tris (pH 7.4), 2.5 mM MgCl2, and 0.5% NP-40, protease and phos-
phatase inhibitors], and nuclei were resuspended in digestion buffer 
[10 mM tris (pH 7.4), 10 mM NaCl, 5 mM MgCl2, and 2 mM CaCl2, 
protease and phosphatase inhibitors] and subjected to digestion with 
MNase (0.01 U/l) (Worthington Biochemical Co.) at 37°C. Undi-
gested chromatin was pelleted by centrifugation at 1500g for 2 min, 
and 14C and 3H activity in supernatant and undigested chromatin 
were measured with a liquid scintillation counter (LS 6500, Beckman 
Coulter). Readings were corrected for 14C bleed through into the 
3H channel. Graphs show one representative experiment of three 
biological replicates.
SNAP-tag histone imaging
Cells were plated in Lab-Tek II Chamber slides (Labclinics) 24 hours 
after siRNA transfection. SNAP labeling was initiated 48 hours after 
transfection (24 hours after plating). For quench-chase-pulse 
experiments, cells were incubated with 5 M SNAP-Cell Block 
(S9106S, New England Biolabs) for 30 min at 37°C. After two PBS 
washes, cells were incubated in medium for 30 min, followed by two 
washes. Cells were incubated in medium for the chase period (6 to 
7 hours). Cells were incubated with 1 M TMR-Star (S9105S, New 
England Biolabs) for 30 min, washed twice, incubated in medium 
for 30 min, washed twice, preextracted for 5 min in 0.2% Triton 
X-100/PBS on ice, and fixed for 10 min in 4% PFA.
DNA fiber assay and DNA combing
For fiber assays, 30 hours after siRNA transfection, U-2-OS cells were 
pulsed with 10 M 5-iodo-2′-deoxyuridine (IdU) (Sigma-Aldrich) 
for 10 min, followed by 20-min labeling with 100 M CldU (MP 
Biomedicals). Cells resuspended in 2 l of ice-cold PBS were incu-
bated with 7 l of spreading buffer [200 mM tris-HCl (pH 7.5), 0.5% 
SDS, and 50 mM EDTA] for 3 min on a slide, and DNA fibers were 
stretched by tilting. After fixation with methanol/acetic acid (3:1), 
DNA was denatured with 2.5 M HCl and blocked (PBS with 1% BSA 
and 0.1% Triton X-100) before staining with primary antibodies. 
Single-molecule analysis of DNA replication by molecular combing was 
performed as described in protocol 36 available from the EpiGeneSys 
Network of Excellence website. In brief, after 30 hours of siRNA 
transfection, U-2-OS cells were labeled with 10 M IdU (Sigma- 
Aldrich) for 10 min, followed by 20-min labeling with 100 M 
CldU (MP Biomedicals). Cells were harvested immediately after the 
pulse and molded into low-melting agarose plugs. Plugs were treated 
with proteinase K buffer, melted at 67°C, and then digested by 
-agarase. DNA was combed on silanized coverslips (Genomic Vision), 
denatured by 2.5 M HCl, and probed by the primary antibodies. 
Graphs show one representative experiment of two biological repli-
cates, and lines represent medians. Images for both assays were col-
lected using a DeltaVision system (Applied Precision) with a UApo/340 
40×/1.35 NA oil objective lens, and the length of CldU- labeled tracks 
was measured with SoftWoRx 5.0.0 (Applied Precision).
Chromatin fractionation
U-2-OS cells were transfected with TLK2 siRNA and treated with 
or without UCN-01 for 2 hours. Soluble proteins were removed 
by pre extraction with cold CSK-T buffer containing protease/ 
phosphatase inhibitors on ice for 5 min, and proteins associated 
with chromatin were subjected to Western blotting. Results are rep-
resentative of two biological replicates.
Pulsed-field gel electrophoresis
U-2-OS cells were transfected with siRNA for 24 hours and treated 
with UCN-01 for 4 hours or irradiated with 20 Gy of ionizing radi-
ation. Cells (1 × 106) were molded into 1% low-melting agarose plugs 
(InCert Agarose, Lonza), followed by treatment with proteinase K 
buffer [10 mM tris-Cl (pH 7.5), 50 mM EDTA, 1% N-laurylsarcosyl, 
proteinase K (2 mg/ml)] at 50°C for 48 hours. Plugs were then sub-
jected to PFGE (1% agarose, CHEF-DR II system; Bio-Rad Labora-
tories; 120° angle, 60- to 240-s switch time, and 4 V/cm) for 20 hours. 
DNA was visualized by ethidium bromide staining. Quantification 
was performed using ImageJ software.
Statistical analysis
Statistical analysis was performed using Prism 6 (GraphPad Soft-
ware), and the n and tests used were stated in the figure legends. 
Statistical tests were performed and are only reported in figures and 
figure legends, where n ≥ 3. Statistical analysis of TCGA data sets is 
described in Supplementary Materials and Methods.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/4/8/eaat4985/DC1
Supplementary Materials and Methods
Fig. S1. TLK2 is required for efficient DNA replication.
Fig. S2. TLK2 is required for replication-coupled chromatin assembly.
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Fig. S3. Sustained depletion of TLK activity leads to DNA damage and checkpoint-induced G1 
arrest.
Fig. S4. TLK2 depletion causes genomic instability that is amplified by checkpoint and PARP 
inactivation.
Fig. S5. Analysis of TLK status in cancer.
Table S1. TCGA cohort designations.
Table S2. Chromosome locations of genes analyzed.
Table S3. Analysis of correlated gene expression.
Table S4. Survival analysis of TCGA patient data.
Table S5. Multivariate survival analysis of TCGA patient data.
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